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CASE
A 23-year-old man presented to an urgent care office with a 2-week history of rectal pain and scant
rectal bleeding. In the few days leading up to his presentation, he also had a fever of 101° F (38.3°
C), inguinal lymphadenopathy, and urinary retention.
History
About 6 months earlier, the patient had been treated for an unknown type of lymphoma and was
now in remission. He is bisexual and has been in an exclusive relationship with another man for
the past 6 months. Both men had been screened for sexually transmitted infections (STIs) before
becoming intimate and all testing was negative. They used condoms irregularly, and the patient
had engaged in receptive anal intercourse. Neither the patient nor his partner had a history of STIs,
nor any lesions or symptoms concerning for STIs.
Physical examination
The patient had tender inguinal lymphadenopathy and exquisite rectal pain that precluded a digital
rectal examination beyond the tip of the examiner’s finger. He had a small, healing anal fissure at
the 6 o’clock location and no other lesions elsewhere on the body or anogenital region.
Examination of the rest of the body (including the genitals) was unrevealing.
Diagnostic testing
Due to the patient’s lack of health insurance, the diagnostic workup was restricted to rectal testing
for gonorrhea, chlamydia, and herpes simplex virus (HSV). Testing for HIV and syphilis was
deferred so he could obtain this testing at a free clinic. Other tests that were considered but not
done in the interest of cost reduction were a complete blood cell count and CT imaging of the
pelvis to rule out an abscess or other abnormality. Urinalysis was considered but not done because
the patient was unable to provide a spontaneous sample at the time of his visit.

DIFFERENTIAL DIAGNOSIS
• gonorrhea
• chlamydia
• proctitis caused by HSV
• abscess of the colon

OUTCOME
The patient was treated empirically for gonorrhea and chlamydia with azithromycin (1 g orally)
and ceftriaxone (250 mg IM), as well as HSV (acyclovir 400 mg orally every 8 hours). A colonic
abscess was considered due to the anal fissure and history of anal intercourse; ciprofloxacin and
metronidazole were prescribed empirically to cover this possibility. Two days later, polymerase
chain reaction (PCR) testing isolated HSV type 2 from the rectal sample. The patient was
diagnosed with proctitis caused by HSV type 2. Chlamydia and gonorrhea testing was negative.

Acyclovir was continued, while ciprofloxacin and metronidazole were discontinued. Over the 10
days of therapy, his symptoms gradually resolved.

DISCUSSION
HSV is a globally prevalent infection that exists as types 1 and 2. HSV type 1 typically is associated
with nonsexual transmission during childhood and usually causes orolabial lesions; HSV type 2 is
more commonly transmitted sexually and classically causes genital lesions. Both HSV types can
cause symptoms in other areas (for example, oral HSV type 2) due to sexual behaviors.
About 50 million Americans are infected with HSV type 2.1 Infected persons experience
symptomatic flares throughout their lifetime, with the virus otherwise remaining dormant in the
sacral ganglia. HSV infections also may be subclinical, so many infected patients are not
diagnosed.2 Fewer than 20% of patients with HSV type 2 have recognized genital herpes.3
Unbeknownst to many infected individuals, HSV type 2 can be sexually transmitted due to
subclinical intermittent shedding of the virus via anterograde axonal transport to the skin and
mucosal epithelia in the anogenital region.2 Studying a large cohort of HSV type 2-seropositive
patients, Tronstein and colleagues found that on average, asymptomatic patients shed the virus on
10% of days compared with symptomatic patients, who shed the virus on 20% of days.4 Although
rates varied, the quantity of virus shed was similar between patient groups; therefore, transmission
risk does not differ between asymptomatic and symptomatic patients during these subclinical
genital shedding episodes.4
Transmission occurs through direct contact with infected mucocutaneous surfaces or genital/oral
secretions. Inoculation of the virus most commonly occurs at mucous membranes such as the
orogenital regions or through small disruptions in the skin where epithelial cells and nerve endings
become infected. Primary infection is followed by retrograde axonal transport to the sacral ganglia
where the virus establishes its chronic infection.
Proctitis, or inflammation located in but not confined to the rectum, is an uncommon manifestation
of HSV type 2 (Figure 1). Acute proctitis among patients who have recently practiced receptive
anal intercourse usually is sexually acquired.2 Typical pathogens for sexually transmitted proctitis
include Chlamydia trachomatis, Neisseria gonorrhoeae, HSV, and Treponema pallidum.2
Symptoms of HSV proctitis typically begin 1 to 3 weeks after exposure and include anorectal pain,
tenesmus, difficulty in urination, sacral paresthesias, fever, and inguinal adenopathy.5 The classic
vesicular lesions associated with HSV type 2 may not be visible on direct physical examination
and can sometimes be indistinguishable from an anal fissure.5
Modalities used to diagnose HSV (regardless of the anatomic site) include viral cultures, PCR, and
herpes serology. PCR has a greater sensitivity than the traditional viral culture, and results can be
available within hours.6 The CDC recommends additional testing for N. gonorrhoeae,
C. trachomatis, and T. pallidum, as well as examination by anoscopy in patients suspected to have
sexually transmitted proctitis.2 Mucosal friability or ulcerations, mucopurulent exudate, and
external or perianal vesicles may be visualized through the anoscope in patients with HSV
proctitis.5 Patients with severe rectal pain may not be able to tolerate such a procedure; consider

general anesthesia or sedation if necessary.5 Alternatively, less-invasive testing may be performed
as was done in this case.
In a case of suspected sexually transmitted proctitis, empiric therapy should be initiated for N.
gonorrhoeae and C. trachomatis before results of laboratory tests are available. If clinical
suspicion of HSV infection is high, also start therapy for HSV. Treatment regimens vary with
initial versus recurrent episodes of genital HSV, as well as suppressive therapy for patients with
six or more outbreaks per year (Table 1). Men treated for sexually transmitted proctitis should
abstain from sexual intercourse until they and their partner(s) have been treated and symptoms
resolved. In addition to chlamydia, gonorrhea, and HSV, all patients with suspected sexually
transmitted proctitis should be tested for HIV and syphilis, with repeat HIV testing in 3 months.2
Because the anogenital lesions of sexually transmitted proctitis are associated with a 50% to 700%
increase in HIV transmission, the diagnosis of sexually transmitted proctitis in an HIV-negative
man who has sex with men should be considered a sentinel event necessitating education and riskreduction counseling.7
Despite the high prevalence of HSV worldwide, routine screening is not recommended, and HSV
testing is not part of general testing for STIs.2 Patients who participate in high-risk sexual behaviors
should receive one-on-one counseling about preventing STIs and HIV. Additional counseling
should involve education about HSV prevalence, chronicity, subclinical shedding, transmission,
and typical/atypical presentations as that information may not be well understood in the general
population. Because most patients who are seropositive for HSV type 2 are unaware of their
infection status and screening is not recommended, patients must understand how to protect
themselves.

CONCLUSION
As this case illustrates, the presentation of HSV infections can be variable and include neurologic
abnormalities such as urinary retention. A high index of suspicion is essential for recognizing this
very common infection in its less common manifestations.
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TABLE 1. Oral treatment regimens for HSV infections2
Therapy for initial genital HSV infections
• Acyclovir 400 mg three times a day for 7 to 10 days
• Acyclovir 200 mg fi ve times a day for 7 to 10 days
• Valacyclovir 1 g twice a day for 7 to 10 days
• Famciclovir 250 mg three times a day for 7 to 10 days
Episodic therapy for recurrent genital HSV infections
• Acyclovir 400 mg three times a day for 5 days
• Acyclovir 800 mg twice a day for 5 days
• Acyclovir 800 mg three times a day for 2 days
• Valacyclovir 500 mg twice a day for 3 days
• Valacyclovir 1 g once a day for 5 days
• Famciclovir 125 mg twice a day for 5 days
• Famciclovir 1 g twice a day for 1 day
• Famciclovir 500 mg once, followed by 250 mg twice
a day for 2 days
Suppressive therapy for recurrent genital herpes
• Acyclovir 400 mg twice a day
• Valacyclovir 500 mg once a day
• Valacyclovir 1 g once a day
• Famciclovir 250 mg twice a day

